After the law was passed in July 2018, doctors wrote fewer and
shorter prescriptions for opioids, researchers report in JAMA
Network Open.
"The policy was intended to reduce the quantity prescribed but it
was not expected to decrease opioid use overall," said study
coauthor Dr. Juan Hincapie-Castillo of the University of Florida
College of Pharmacy in Gainesville.
"But fewer people were getting opioids. That means the law led not
only to a reduction in the quantity dispensed, but also to a
reduction in the initial decision to prescribe."
At this point it's not clear what medications doctors were choosing
to prescribe in place of opioids, Hincapie-Castillo said. "We know
that some patients are not getting opioids, so, are they getting
more non-steroidal anti-inflammatory drugs, like ibuprofen or
naproxen, or other medications, like gabapentin?" he said. "We don't
know yet."
While it's good to see a reduction in the amount of opioids
prescribed overall, Hincapie-Castillo worries that laws like the one
in Florida might also make doctors less likely to write
prescriptions for patients with chronic pain.
"Anecdotally around the country, patients with chronic pain are
being tapered off of opioids," he said. "Their dose is being
decreased or stopped altogether."
Beyond that, laws like the one in Florida might be too broad,
Hincapie-Castillo said. "Pain from a tooth extraction is not the
same as that from a bone fracture," he explained. "We have to be
sure we are doing everything in our power to control the opioid
crisis. But prescribing restrictions need to come down somewhere in
the middle because of the effects they can have on patients who
legitimately should have these medications."
To take a closer look at the impact of the new Florida opioid law,
Hincapie-Castillo and his colleagues analyzed pharmacy prescription
claims for opioids dispensed from January 2015 through March 2019 in
a single health plan covering more than 45,000 people.
[to top of second column] |
To focus on patients who were newly prescribed opioids and continuously using
the medication, the researchers made sure none had a prescription for the drugs
in the previous 180 days. In the end, Hincapie-Castillo and his colleagues
identified 8,375 patients with 10,583 unique new opioid prescriptions. There
were more prescriptions than patients because individual patients might have had
a prescription for opioids more than once during the years covered by the study,
Hincapie-Castillo explained.
Before the new legislation, 5.5 per 1,000 patients started a new prescription
for opioids. That dropped to 4.6 per 1,000 after the law was implemented.
After the law was in effect, there was also an immediate decrease of 0.48
patients per 1,000 in monthly users of hydrocodone, which is often sold in
combination formulas containing ibuprofen or other over the counter pain
medicines.
Other weaker opioids also saw a 0.24 per 1,000 drop in monthly users after the
law.
The average number of days included in opioid prescriptions also dropped from
5.4 to 4.2 and continued to decrease over the eight months following
implementation of the law.
"The study shows that if you change the law, you will likely change prescriber
behavior," said Dr. Yury Khelemsky, an associate professor of anesthesiology,
perioperative and pain medicine at the Icahn School of Medicine at Mount Sinai
in New York City. "And that make sense because physicians tend to be pretty
compliant with regulatory issues."
With the current opioid crisis, it makes sense to try to change physician
prescribing behavior, said Khelemsky, who was not affiliated with the new
research. "Clearly there are a lot of people suffering from addiction and a lot
of people dying from these medications," he added. "I think it's a good idea to
have physicians be more careful with prescribing and essentially keeping tabs on
the patient."
SOURCE: https://bit.ly/2Px4I9a JAMA Network Open, online February 28, 2020.
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |